<!--
MVT in Silico, a drug development company.
http://mvtsilico.com
Copyright: MVT in Silico, 2025.
-->
<html>
<head>
 <meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Team.</title>
<link rel="stylesheet" href="styles.css">
</head>
<body>
<!--- -- Navigation menu from: https://codepen.io/erikterwan/pen/EVzeRP -->

<!--- Main content -->
<main>
<br><br><br>
<h1 class="left-text" style="color: black;">Team.</h1>
<br>
	<p>We are an expert team consisting of computational modellers, biophysicists, pharmacologists, mechanical engineers, and university
	professors. In addition, the company has two employees as of 2025.</p><br>
	<h5>Dr. S. R. Kharche. President, CEO, and Chief Science Officer. (founder)</h5>
<p>Dr. Kharche is a seasoned scientist and an expert in scientific computing. His expertise includes R&D software development,
computational physiology, cardiovascular sciences, blood flow fluid dynamics, and molecular dynamics. He has published a wide spectrum of journal
<a href="https://scholar.google.com/citations?hl=en&user=hwkcYRMAAAAJ&view_op=list_works&sortby=pubdate">articles</a> which
has led to the inception of MVT <i>in</i> Silico company. Over the past two years (2023 to 2025), he has gained valuable
hands on experience of the business ecosystem in Canada and elsewhere. He is an ideal founder to lead the Company in its 
scientific and technical programs.<br> <br>
Founder's resumes: <a href="SanjayKharche_ShortResume_June2025.pdf">short</a> 
and <a href="SanjayKharche_Resume_LongJune2025.pdf">long</a>.</p>

<h5>Prof. D. G. Welsh. Chief Scientific Advisor.</h5>
<p>Dr. (Prof) Donald G. Welsh is a world renowned Professor of Physiology and Pharmacology at Western University, Canada,
and a distinguished scientist at the Robarts Research Institute. A leading expert in vascular biology and ion
channel physiology, his research focuses on the regulation of blood flow, arterial function, and the role of
potassium channels in cardiovascular health. With over 100 high quality peer reviewed scientific publications,
his work has garnered more than 6,000 citations, reflecting its broad impact. His leadership extends to
editorial roles for prestigious journals and advisory positions for international scientific organizations.<br>
Recognized with awards for his contributions to vascular physiology, he bridges foundational research and clinical 
innovation. Dr. Welsh’s lab is renowned for pioneering discoveries in cellular communication within microvascular 
networks. He is the ideal advisor for our life sciences and biotech programs leading us towards patents.<br><br>
Prof. Welsh’s brief resume can be found <a href="DonWelsh_ShortResume_June2025.pdf">here</a>.</p>
<p><b>Company Employees</b><br>
  <ul>
	<li>Harpreet Kaur. Business Manager. (April 2025 to present).</li>
  <li>Yihang Cheng. R & D officer. (April 2025 to August 2025).</li>
	<li>Alexis Watson (January 2026 onwards).</li>
  </ul>
	<br>
</main>


</body>
</html>
